Explore recent issues of Contract Pharma covering key industry trends.
Read the full digital version of our magazine online.
Stay informed! Subscribe to Contract Pharma for industry news and analysis.
Get the latest updates and breaking news from the pharmaceutical and biopharmaceutical industry.
Discover the newest partnerships and collaborations within the pharma sector.
Keep track of key executive moves and promotions in the pharma and biopharma industry.
Updates on the latest clinical trials and regulatory filings.
Stay informed with the latest financial reports and updates in the pharma industry.
Expert Q&A sessions addressing crucial topics in the pharmaceutical and biopharmaceutical world.
In-depth articles and features covering critical industry developments.
Access exclusive industry insights, interviews, and in-depth analysis.
Insights and analysis from industry experts on current pharma issues.
A one-on-one video interview between our editorial teams and industry leaders.
Listen to expert discussions and interviews in pharma and biopharma.
A detailed look at the leading US players in the global pharmaceutical and BioPharmaceutical industry.
Browse companies involved in pharmaceutical manufacturing and services.
Comprehensive company profiles featuring overviews, key statistics, services, and contact details.
A comprehensive glossary of terms used in the pharmaceutical and biopharmaceutical industry.
Watch in-depth videos featuring industry insights and developments.
Download in-depth eBooks covering various aspects of the pharma industry.
Access detailed whitepapers offering analysis on industry topics.
View and download brochures from companies in the pharmaceutical sector.
Explore content sponsored by industry leaders, providing valuable insights.
Stay updated with the latest press releases from pharma and biopharma companies.
Explore top companies showcasing innovative pharma solutions.
Meet the leaders driving innovation and collaboration.
Engage with sessions and panels on pharma’s key trends.
Hear from experts shaping the pharmaceutical industry.
Join online webinars discussing critical industry topics and trends.
A comprehensive calendar of key industry events around the globe.
Live coverage and updates from major pharma and biopharma shows.
Find advertising opportunities to reach your target audience with Contract Pharma.
Review the editorial standards and guidelines for content published on our site.
Understand how Contract Pharma handles your personal data.
View the terms and conditions for using the Contract Pharma website.
What are you searching for?
How early research provides the crucial evidence needed to conduct clinical trials
March 5, 2018
By: Kristin Brooks
Managing Editor, Contract Pharma
A record number of personalized medicines were approved by the FDA in 2017, and now account for approximately one in four New Drug Approvals. Conducting research and development in prevalent diseases can be difficult; rare disease research comes with a whole new set of challenges. When studying rare diseases, it often proves difficult to identify study participants for clinical trials due to low prevalence. As a result, animal models are used to study the effects of investigative therapies during preclinical trials. However, having the right animal model is key – it paves the path for conducting the right clinical trial by understanding a potential drug’s mechanism of action, its effects on relevant biomarkers and when and how it can be used effectively in humans. Antti Nurmi, Ph.D., MSc, Managing Director, Discovery Services, at Charles River Laboratories (CRL) discusses how the growth of orphan drug research impacts preclinical services and how early research in rare diseases can provide the crucial evidence needed to conduct clinical trials. –KB Contract Pharma: How has the growth of orphan drug research impacted preclinical services? Antti Nurmi: The growth in orphan drug discovery has resulted in a need to review the overall drug development process from a new perspective. There is typically no good starting point for in vitro or in vivo biology of a given orphan disease, which means that drug development programs are often highly tailored and customized. This requires partners to harness capabilities and technologies from across therapeutic areas and customize them to the readouts and conditions of a specific rare disease. Charles River has successfully provided rare and orphan disease drug development services, with Huntington’s disease as one of the most comprehensive examples. Charles River helps to design custom approaches for rare and orphan diseases by combining target agnostic platforms, including disease biology relevant biochemical assays, in vitro and in vivo models and assays. CP: What is the significance of animal models in rare disease research? AN: Discussions about rare and orphan diseases typically surround single gene mutations, which result in a disease phenotype at the cellular and tissue level. While in vitro animal models can mimic the human disease biology at the cell and tissue levels, in vivo models can be more challenging. The disease phenotype in the animal model may significantly differ from the human disease manifestation. Therefore, it is critical to understand the limitations of the animal models, and identify the specific scientific questions that can be answered reliably. Although limited, animal models of disease are essential in understanding disease biology, as they contain the full interactive physiology of an animal, which would be very difficult to reliably simulate in in vitro systems. CP: What are the challenges of finding the right research model? AN: Often there is a disconnect between the underlying disease biology and disease phenotype in an animal model. It may be that we can see the effects of single gene mutations at the biochemical and cellular/tissue level, but we do not see the consequences of such pathology in the animal’s behavior and abilities in the same way as in human patients. Also, it is worth mentioning that the life span and disease evolution in humans compared to animal models is different, making translation of animal model work into the clinic more challenging. CP: How do you help clients address these? AN: Through our expertise across various rare and orphan diseases and historical collaborations, we bring a unique understanding about both opportunities and limitations of animal models. We continuously engage with key opinion leaders, pharma/biotech and foundations to provide the best possible tools available to be used in drug programs. We consider ourselves more as partners than service providers to our clients. CP: How does this early research method impact clinical trials? AN: Early research provides the crucial evidence needed to conduct clinical trials. If there is not a sufficient amount of evidence about the efficacy and safety of novel therapies, there is no point of advancing drugs to clinical trials. Besides ethical justifications, thoroughly and reliably conducted early research reduces the risk of failure related to expensive clinical trials at later stages. Development of a given therapy is increasingly becoming more expensive, and easily requires several years of work to get the therapy to the patient.
Enter your account email.
A verification code was sent to your email, Enter the 6-digit code sent to your mail.
Didn't get the code? Check your spam folder or resend code
Set a new password for signing in and accessing your data.
Your Password has been Updated !